利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.054 秒)

    Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains
    1.
    发明授权
    Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains 失效
    使用减毒菌株制备针对铜绿假单胞菌的疫苗的方法

    公开(公告)号：US5861163A

    公开(公告)日：1999-01-19

    申请号：US773330

    申请日：1996-12-24

    申请人： Hyun Su Kim ,  Wan Je Park ,  Wang Don Yoo ,  Kap Soo Noh ,  Dong Eok Lee ,  Suk Hoon Ha ,  Ree An Yoo ,  Nam Joong Lee ,  Yang Je Cho ,  Sun Pyo Hong ,  Je Hak Kim ,  Dal Hyun Kim ,  Young Gi Kim

    发明人： Hyun Su Kim ,  Wan Je Park ,  Wang Don Yoo ,  Kap Soo Noh ,  Dong Eok Lee ,  Suk Hoon Ha ,  Ree An Yoo ,  Nam Joong Lee ,  Yang Je Cho ,  Sun Pyo Hong ,  Je Hak Kim ,  Dal Hyun Kim ,  Young Gi Kim

    IPC分类号： A61K39/00 ,  A61K39/104 ,  C07K14/21 ,  C07K16/12 ,  C12N7/04 ,  A61K39/108 ,  A61K39/02

    CPC分类号： C07K16/1214 ,  A61K39/104 ,  C07K14/21 ,  A61K39/00

    摘要： The present invention relates to a vaccine prepared from an attenuated Pseudomonas aeruginosa strains which are obtained by isolating Pseudomonas aeruginosa in a pure state according to the Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035) strains. In addition, the present invention relates to a process for preparing the vaccine for immunization against Pseudomonas aeruginosa infection which contains cell wall proteins having molecular weights ranging from 10,000 to 100,000. The cell wall protein component of the attenuated strain is non-pathogenic and safe, and exhibits excellent antibody formation capacity and is useful for preparation of a vaccine and therapeutic agent. The cell wall proteins exhibit an excellent cross-protective efficacy for various Pseudomonas aeruginosa strains and a superior antibody inducing property.

    摘要翻译： 本发明涉及由减毒铜绿假单胞菌菌株制备的疫苗，其通过根据Fisher-Devlin免疫型分离纯状态的绿脓假单胞菌，然后重复纯化分离的菌株，特别是CFCPA 10142（KCCM 10029），CFCPA 20215 （KCCM 10030），CFCPA 30720（KCCM 10031），CFCPA 40057（KCCM 10032），CFCPA 50243（KCCM 10033），CFCPA 60534（KCCM 10034）和CFCPA 70018（KCCM 10035）菌株。 此外，本发明涉及一种制备用于免疫铜绿假单胞菌感染的疫苗的方法，其包含分子量范围为10,000至100,000的细胞壁蛋白。 减毒菌株的细胞壁蛋白质组分是非致病性和安全性的，并且表现出优异的抗体形成能力，并且可用于制备疫苗和治疗剂。 细胞壁蛋白对于各种铜绿假单胞菌菌株表现出优异的交叉保护作用和优异的抗体诱导性质。

    COMBINED FORMULATION WITH IMPROVED STABILITY
    9.
    发明申请
    COMBINED FORMULATION WITH IMPROVED STABILITY 审中-公开
    具有改进的稳定性的组合配方

    公开(公告)号：US20140044784A1

    公开(公告)日：2014-02-13

    申请号：US14004755

    申请日：2012-03-14

    申请人： Je Hak Kim ,  Kyung Wan Nam ,  Ju Won Park

    发明人： Je Hak Kim ,  Kyung Wan Nam ,  Ju Won Park

    IPC分类号： A61K9/51 ,  A61K31/505 ,  A61K31/616

    CPC分类号： A61K9/51 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/5042 ,  A61K9/5084 ,  A61K31/22 ,  A61K31/40 ,  A61K31/47 ,  A61K31/505 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

    摘要： Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.

    摘要翻译： 公开了用于治疗心血管疾病的口服给药的组合制剂，包括（a）直径为7.5mm以下的胆固醇降低剂微片，其含有胆固醇降低剂，其稳定剂和药学上可接受的赋形剂，并且具有 涂布层，以及（b）直径为7.5mm以下的抗血栓形成剂微片或微丸，其含有抗血栓剂和药学上可接受的赋形剂，并且在其表面包括肠溶衣膜。 该制剂可以根据组合处方改善治疗依从性，并且被控制以使胆固醇降低剂在胃肠道中释放，并且抗血栓形成剂在肠中释放，从而抑制药物之间的反应和副作用， 诱导这些药物在体内的协同作用，并达到改善的稳定性。